A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
NGM Biopharmaceuticals, Inc.
Start Date
November 1, 2015
End Date
April 30, 2019
Administered By
Medicine, Gastroenterology
Awarded By
NGM Biopharmaceuticals, Inc.
Start Date
November 1, 2015
End Date
April 30, 2019